<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Site of action of venom, clinical features, tests, and management</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Site of action of venom, clinical features, tests, and management</h1>
<div class="graphic"><div class="figure"><div class="ttl">Site of action of venom, clinical features, tests, and management</div><div class="cntnt"><table cellspacing="0"><colgroup width="15%"></colgroup><colgroup span="3" width="28%"></colgroup> <tbody> <tr> <td class="subtitle1">Site of action</td> <td class="subtitle1">Clinical features</td> <td class="subtitle1">Ancillary testing</td> <td class="subtitle1">Management</td> </tr> <tr class="divider_bottom"> <td>Local tissue</td> <td> <p>Pain</p> <p>Fang marks</p> <p>Swelling</p> <p>Blistering</p> <p>Ecchymoses</p> <p>Tissue necrosis</p> Lymph node swelling and tenderness</td> <td> </td> <td> <p>Antivenom</p> <p>Manage signs of compartment syndrome (Rare)</p> </td> </tr> <tr class="divider_bottom"> <td>Neuromuscular junction</td> <td> <p>Ptosis </p> <p>Diplopia</p> <p>Dysphagia</p> <p>Bulbar palsy: "drooling" pooling of secretions in pharynx</p> <p>Dyspnea</p> Limb weakness</td> <td> <p>Positive neostigmine trial indicates post-synaptic paralysis responsive to antivenom and anticholinesterase*</p> <p>Low maximal inspiratory and expiratory forces</p> </td> <td> <p>Antivenom</p> <p>Anticholinesterase (eg, neostigmine)*</p> <p>Maintain and support airway and breathing, as needed </p> </td> </tr> <tr class="divider_bottom"> <td>Coagulopathy</td> <td> <p>Epistaxis </p> <p>Gingival oozing</p> <p>Bleeding from venipuncture site</p> <p>Ecchymoses and bruising</p> Clinically evident bleeding (hemoptysis, hematemesis, hematuria, intracranial hemorrhage)</td> <td> <p>Thrombocytopenia (Complete blood count)</p> <p>Anemia</p> <p>Prolonged INR or aPTT</p> <p>Decreased fibrinogen</p> <p>Increased fibrin degradation products or  D-dimer</p> <p>20-minute whole blood clotting test (resource-limited settings)<sup>¶</sup></p> </td> <td> <p>Antivenom primary treatment</p> <p>Blood products (eg, whole blood, fresh frozen plasma, or platelets) only if life-threatening bleeding and, when available, <strong>after</strong> antivenom administration</p> Heparin, aminocaproic acid <strong>not</strong> helpful</td> </tr> <tr> <td>Shock</td> <td> <p>Hypotension</p> <p>Tachycardia</p> <p>Signs of poor perfusion (prolonged capillary refill, decreased urine output, altered mental status)</p> </td> <td> <p>Central pressure monitoring </p>  </td> <td> <p>Antivenom</p> <p>Intravenous isotonic fluids (eg, normal saline) and vasoactive infusions to maintain perfusion pressure depending upon whether shock is hypovolemic, cardiogenic, or both</p> </td> </tr> <tr> <td>Rhabdomyolysis            </td> <td> <p>Red or brown urine</p> <p>Oliguria    </p> </td> <td> <p>Rapid urine dipstick positive for blood with microscopic urinalysis showing no red blood cells</p> <p>Positive urine for myoglobin</p> <p>Increased serum creatine kinase, potassium, creatinine, and/or blood urea nitrogen</p> <p>EKG changes indicating hyperkalemia</p> </td> <td> <p>Intravenous normal saline in volumes sufficient to reestablish urinary output<sup>Δ</sup></p> <p>Hemodialysis, as needed, for acute kidney injury</p> <p> </p> </td> </tr> </tbody></table></div><div class="graphic_lgnd">* Refer to UpToDate topics on snakebites worldwide for specific guidance on performing a Tensilon (edrophonium) test and for recommended dosing of neostigmine in snakebite victims with a positive test. <br/>¶ The whole blood clotting test (WBCT) has also been considered a useful bedside screening test when more formal coagulation testing is not available; failure of the blood to clot in a clean glass tube after 20 minutes has been considered evidence of severe hypofibrinogenemia. The WBCT has low sensitivity but high specificity. Thus, a positive test is a reasonable indication for antivenom administration. However, a negative test does <strong>not</strong> mean that antivenom should be withheld, especially if there are clinical features of coagulopathy (eg, blood oozing at puncture sites, bleeding gums, or epistaxis).<br/>Δ Antivenom may attenuate rhabdomyolysis but will not reverse it for selected snakes. Refer to UpToDate topics on management of snakebites worldwide.</div><div id="graphicVersion">Graphic 73959 Version 9.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
